Mg-ZIF nanozyme regulates the switch between osteogenic and lipogenic differentiation in BMSCs via lipid metabolism

Jinying Li,Yongshao Chen,Dingsheng Zha,Chunhui Wu,Xiaofen Li,Li Yang,Hui Cao,Shexing Cai,Yuebo Cai
DOI: https://doi.org/10.1186/s12944-024-02083-3
2024-03-26
Lipids in Health and Disease
Abstract:The accumulation of reactive oxygen species (ROS) within the bone marrow microenvironment leads to diminished osteogenic differentiation and heightened lipogenic differentiation of mesenchymal stem cells residing in the bone marrow, ultimately playing a role in the development of osteoporosis (OP). Mitigating ROS levels is a promising approach to counteracting OP. In this study, a nanozyme composed of magnesium-based zeolitic imidazolate frameworks (Mg-ZIF) was engineered to effectively scavenge ROS and alleviate OP. The results of this study indicate that Mg-ZIF exhibits significant potential in scavenging ROS and effectively promoting osteogenic differentiation of bone mesenchymal stem cells (BMSCs). Additionally, Mg-ZIF was found to inhibit the differentiation of BMSCs into adipose cells. In vivo experiments further confirmed the ability of Mg-ZIF to mitigate OP by reducing ROS levels. Mechanistically, Mg-ZIF enhances the differentiation of BMSCs into osteoblasts by upregulating lipid metabolic pathways through ROS scavenging. The results indicate that Mg-ZIF has potential as an effective therapeutic approach for the treatment of osteoporosis.
biochemistry & molecular biology,nutrition & dietetics
What problem does this paper attempt to address?
The problem that this paper attempts to solve is that the accumulation of reactive oxygen species (ROS) in the bone marrow microenvironment leads to the decline of the osteogenic differentiation ability and the enhancement of the adipogenic differentiation ability of bone marrow mesenchymal stem cells (BMSCs), and ultimately affects the development of osteoporosis (OP). The author proposes that osteoporosis can be countered by reducing ROS levels. To this end, the research team designed a magnesium - based zeolitic imidazolate framework nanoenzyme (Mg - ZIF) to effectively scavenge ROS and promote the osteogenic differentiation of BMSCs by regulating the lipid metabolism pathway while inhibiting their differentiation into adipocytes. The experimental results show that Mg - ZIF can effectively reduce ROS levels in vitro and in vivo, promote the osteogenic differentiation of BMSCs, and reduce adipogenic differentiation, thus having a potential therapeutic effect on osteoporosis. The key points of the paper are as follows: - **Problem background**: The accumulation of ROS in the bone marrow microenvironment leads to the weakening of the osteogenic differentiation and the enhancement of the adipogenic differentiation of BMSCs, which is an important factor in the development of osteoporosis. - **Solution**: Designed and synthesized the Mg - ZIF nanoenzyme, and utilized its ability to scavenge ROS to promote the osteogenic differentiation of BMSCs by up - regulating the lipid metabolism pathway and inhibit adipogenic differentiation. - **Experimental verification**: Through in vitro cell experiments and in vivo animal experiments, the effectiveness of Mg - ZIF has been proved. In conclusion, this paper aims to provide a new method for treating osteoporosis by developing the Mg - ZIF nanoenzyme, with the focus on improving the osteogenic differentiation ability of BMSCs by regulating the lipid metabolism pathway.